Alvotech Share Holder Equity 2021-2025 | ALVO

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Alvotech share holder equity from 2021 to 2025. Share holder equity can be defined as the sum of preferred and common equity items

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Alvotech share holder equity from 2021 to 2025. Share holder equity can be defined as the sum of preferred and common equity items

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$226.4B
Amgen (AMGN)	$166.3B
Gilead Sciences (GILD)	$141.3B
Vertex Pharmaceuticals (VRTX)	$122.5B
Bristol Myers Squibb (BMY)	$99.7B
CSL (CSLLY)	$85.2B
GSK (GSK)	$77.9B
Regeneron Pharmaceuticals (REGN)	$61.8B
Alnylam Pharmaceuticals (ALNY)	$42.5B
Argenex SE (ARGX)	$35.2B
BioNTech SE (BNTX)	$27.5B
Royalty Pharma (RPRX)	$20.2B
Insmed (INSM)	$19.6B
Biogen (BIIB)	$19.2B
Illumina (ILMN)	$16.6B
Genmab (GNMSF)	$14.9B
Genmab (GMAB)	$14.7B
Incyte (INCY)	$13.7B
Moderna (MRNA)	$13.4B
Exelixis (EXEL)	$12.4B
BioMarin Pharmaceutical (BMRN)	$11.4B
QIAGEN (QGEN)	$11.2B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Ascendis Pharma (ASND)	$10.4B
Exact Sciences (EXAS)	$9.1B
Verona Pharma American Depositary Share (VRNA)	$8.9B
Bio-Techne Corp (TECH)	$8.7B
Blueprint Medicines (BPMC)	$8.3B
Legend Biotech (LEGN)	$8.1B
Roivant Sciences (ROIV)	$7.7B